Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease (SCD-001)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01522547
First received: January 27, 2012
Last updated: December 24, 2013
Last verified: December 2013
  Purpose

The purpose of the study is to determine the maximum tolerated dose, safety and effect on induction of fetal hemoglobin of pomalidomide in patients with Sickle Cell Disease.


Condition Intervention Phase
Anemia, Sickle Cell
Drug: pomalidomide
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 In Subjects With Sickle Cell Disease

Resource links provided by NLM:


Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) [ Time Frame: Up to 84 days ] [ Designated as safety issue: Yes ]
    Maximum Tolerated Dose


Secondary Outcome Measures:
  • Adverse Events [ Time Frame: Up to 169 days ] [ Designated as safety issue: Yes ]
    Type, frequency, and severity of adverse events, and relationship of adverse events to pomalidomide

  • Absolute fetal hemoglobin change [ Time Frame: UP to 169 days ] [ Designated as safety issue: No ]
    Percent of subjects with an absolute increase of 5% in percent fetal hemoglobin levels during study treatment

  • % total hemoglobin [ Time Frame: Up to 169 days ] [ Designated as safety issue: No ]
    Percent change in total hemoglobin from baseline to highest level

  • Rate of total hemoglobin change [ Time Frame: Up to 169 days ] [ Designated as safety issue: No ]
    Rate of change of total hemoglobin from baseline to highest level

  • Inflammation markers and cytokines [ Time Frame: Up to 169 days ] [ Designated as safety issue: No ]
    Change in serum inflammation markers and cytokines from baseline, during and at end of study treatment


Estimated Enrollment: 12
Study Start Date: August 2007
Study Completion Date: December 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1: 0.5 mg pomalidomide
0.5 mg pomalidomide orally daily for 84 days
Drug: pomalidomide
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Name: CC-4047
Experimental: Cohort 2: 1.0 mg pomalidomide
1.0 mg pomalidomide orally daily for 84 days
Drug: pomalidomide
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Name: CC-4047
Experimental: Cohort 3: 2.0 mg pomalidomide
2.0 mg pomalidomide orally daily for 84 days
Drug: pomalidomide
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Name: CC-4047
Experimental: Cohort 4: 3.0 mg pomalidomide
3.0 mg pomalidomide orally daily for 84 days
Drug: pomalidomide
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Name: CC-4047
Experimental: Cohort 5: 4.0 mg pomalidomide
4.0 mg pomalidomide orally daily for 84 days
Drug: pomalidomide
Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Other Name: CC-4047

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 18 to 60 years, inclusive, at the time of signing the informed consent form
  • Clinically significant Sickle Cell Disease (SCD) documented as Sickle Cell Anemia or Sickle Beta-Zero Thalassemia
  • Clinically significant SCD defined as at least 1 documented pain episode per year averaged over the past 3 years or one episode of active leg ulcers, priapism, or acute chest syndrome over the past 3 years
  • Failed to achieve at least an absolute 5% increase in hemoglobin F while taking Hydroxyurea (HU) or unable to tolerate HU as described by the treating physician and may include but is not limited to lack of efficacy (such as people who have continued to have pain episodes more than 2 times a year or who have had acute chest or multiorgan failure syndromes or an episode of priapism), or other severe side effects while on HU (severe side effects include significant myelosuppression; skin cancer; or cytotoxicity evidenced by gastrointestinal symptoms, dermatological reactions, hepatic enzyme elevations, pulmonary fibrosis or neurological disturbances), or refusal of hydroxyurea therapy by the informed patient
  • Able to adhere to the study visit schedule and other protocol requirements
  • Females must be surgically sterile (post hysterectomy or bilateral oophorectomy) or naturally postmenopausal for at least 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months)
  • Male subjects must agree to use a latex condom during any sexual contact with females of child bearing potential (FCBP) during study drug treatment, during dose interruptions, and for at least 28 days following discontinuation of study drug even if they have undergone a successful vasectomy. Counseling about the requirement for latex condom use during sexual contact with FCBP and the potential risks of fetal exposure must be conducted at a minimum of every 28 days.
  • Male subjects must agree to abstain from donating semen or sperm while taking study drug and for 28 days after stopping study drug.
  • Both males and females must agree to abstain from donating blood while taking study drug and for 28 days after stopping study drug.
  • Both males and females must agree that they will not share study drug and will be counseled about the potential risks of fetal exposure.

Exclusion Criteria:

  • Known positive status for human immune virus (HIV), Hepatitis B; or acute/chronic, active Hepatitis C
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
  • Females of childbearing potential, pregnant or lactating females
  • Any condition, including the presence of laboratory abnormalities, which place the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Subjects unlikely to comply with birth control, medication dosing, or study visit requirements
  • Subjects with severe or life threatening, active, unresolved infections
  • Any of the following laboratory abnormalities derived from the Screening Visit:

    • Platelet count or white blood cell count (WBC) less than the lower limit of normal (LLN)
    • Total hemoglobin less than or equal to 6.0 g/dL
    • Hemoglobin A (HbA) from transfusion greater than 20% at baseline
    • Creatinine greater than Upper Limit of Normal (ULN)
    • Alanine Aminotransferase / Serum Glutamic Pyruvic Transaminase (ALT/SGPT) greater than 3 x ULN
    • Total bilirubin greater than 10 mg/dL
  • Subjects on a chronic transfusion program
  • History of non-catheter related Deep Vein Thrombosis (DVT) or stroke
  • Chronic symptomatic constipation
  • History of cancer (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for at least three years.
  • Use of agents that can induce fetal hemoglobin within 90 days (three months) of Day 1 (i.e. HU, butyrates, decitabine, 5-azacytidine, or erythropoietin)
  • Use of experimental drug or treatment within 30 days of the first dose of study drug
  • History of allergic reaction to thalidomide or lenalidomide
  • Prior desquamating (blistering) rash while taking thalidomide or lenalidomide
  • Greater than or equal to a Grade 2 neuropathy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01522547

Locations
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-2097
Sponsors and Collaborators
Celgene Corporation
Investigators
Study Director: Robert Knight, MD Celgene Corporation
  More Information

No publications provided

Responsible Party: Celgene Corporation
ClinicalTrials.gov Identifier: NCT01522547     History of Changes
Other Study ID Numbers: CC-4047-SCD-001
Study First Received: January 27, 2012
Last Updated: December 24, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Celgene Corporation:
Pomalidomide
Sickle Cell Disease
Fetal Hemoglobin

Additional relevant MeSH terms:
Anemia
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
Thalidomide
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 21, 2014